BioCentury
ARTICLE | Company News

Seattle Genetics, Astellas deal

June 13, 2011 7:00 AM UTC

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-22ME. Agensys submitted an IND last quarter for a Phase I trial of the antibody...